LLY.XETRA Eli Lilly and Company

Healthcare Pharmaceuticals XETRA Stock Exchange
1,256 EUR
Close of Nov 5, 2026
726.03 1,295
Market cap
EUR 1.12T
P/E
47.4x
P/B
31.58x
ROE
70.7%
Dividend yield
0.49%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LLY.XETRA undervalued?

Graham number

The Graham number of Eli Lilly and Company cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Eli Lilly and Company fundamental analysis

No fundamental analysis for Eli Lilly and Company yet.

Eli Lilly and Company stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and…

Full company profile